NEW YORK (GenomeWeb) – T2 Biosystems announced today that it has signed a multi-year deal giving Bayer access to its T2 Magnetic Resonance (T2MR) technology platform for use in its R&D efforts in blood coagulation disorders.

Under the terms of the deal, the companies will use the technology to develop tools and evaluate assays for drug discovery and biomarker research in certain Bayer hemostasis-related programs.

Additional terms were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.